In the BioHarmony Drug Report Database

"Preview" Icon

Sacubitril

Entresto, Neparvis (sacubitril) is a small molecule pharmaceutical. Sacubitril was first approved as Entresto on 2015-07-07. It has been approved in Europe to treat heart failure. Entresto’s patents are valid until 2036-05-09 (FDA).

 

Trade Name

 

Entresto, Neparvis
 

Common Name

 

sacubitril
 

ChEMBL ID

 

CHEMBL3137301
 

Indication

 

heart failure
 

Drug Class

 

Endopeptidase inhibitors

Image (chem structure or protein)

Sacubitril structure rendering